Year Approved (First Funded) | Generic (Trade Name) | Disease (Therapeutic Area) | Study Phase at Funding | PI Institution | Single or Multiple Study Sites | Non-Academic Collaboration at Application |
---|---|---|---|---|---|---|
2012 (2007) | Ivacaftor (Kalydeco) | Cystic Fibrosis Subjects with G551D (Pulmonary) | Phase 2 | Industry | Multiple- 8 sites | Patient group |
2013 (2008) | Topical nitrogen mustard, Meclorethamine (Valchlor) | Mycosis Fungoides (Oncology/Hematology) | Phase 2 | Academic | Multiple- 2 sites | Industry |
2015 (2011) | Asfotase alfa (Strensiq) | Hypophosphatasia (Endocrinology) | Phase 2 | Industry | Multiple- 7 sites | None |
2015 (2008) | Parthyroid Hormone (Natpara) | Hypoparathyroidism (Endocrinology) | Phase 3 | Academic | Single | Industry |
2015 (2007) | Sirolimus (Rapamune) | Lymphangioleiomyomatosis (Pulmonary) | Phase 3 | Academic | Multiple- 8 sites | Patient group & Industry |
2016 (2011) | Cheatham Platinum Stent System | Aortic Wall Injury Associated with Aortic Coarctation (Cardiovascular) | Phase 3 | Academic | Multiple- 19 sites | Industry |
2017 (2009) | Berlin Heart EXCOR Pediatric Ventricular Assist Device | Bridge-to-Heart Transplantation in Children (Cardiovascular) | Phase 2 | Academic | Multiple- 13 sites | None |
2018 (2008) | Fish Oil Triglycerides (Omegaven) | Reversal of Parenteral Nutrition-Associated Cholestasis (Gastrointestinal) | Phase 2 | Academic | Single | None |
2019 (2008) | Tafamidis meglumine/ /Tafamidis free acid (Vyndaqel/Vyndamax) | Familial Amyloid Polyneuropathy (Neurology) | Phase 3 | Industry | Multiple- 8 sites | None |